Resonance Health
Resonance Health is a MedTech company specializing in non-invasive medical imaging analysis, particularly in iron overload and liver disease management. Their portfolio includes post-MRI analysis tools like FerriScan and HepaFatScan, providing quantitative calculations and evaluations essential for disease management and clinical trials.
Short position
Resonance Health (ASX:RHT) has 0.02% of its shares on issue reported as short positions as of 25 Sept 2026, or about 71,783 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in February 2019. RHT is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Resonance Health (RHT) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $15.8MM (source: ASX (Markit))vs $11.2MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- $1.5MM (source: ASX (Markit))vs −$1.7MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (diluted)
- $0.003T (source: Derived: trailing 12 months at year end)vs −$0.004 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- +41.3%FY
- EPS YoY
- n/aTTM
EPS: prior loss, now profit (growth is not meaningful against a loss).
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- 99.9%
- Operating margin
- 9.7%
- Net margin
- 9.6%
- FCF margin
- 16.4%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- 1.71×
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- 4.5×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- 26.1×
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $15.8MM (source: ASX (Markit)) | $11.2MM (source: ASX (Markit)) | $8.6M | $4.4M |
| Gross profit | $15.8MT (source: Derived: trailing 12 months at year end) | n/a | $8.6M | $4.4M |
| Operating income | $1.5MT (source: Derived: trailing 12 months at year end) | n/a | −$879.5K | −$1.6M |
| EBITDA | $2.4MT (source: Derived: trailing 12 months at year end) | n/a | −$381.5K | −$1.2M |
| EBIT | $1.4MT (source: Derived: trailing 12 months at year end) | n/a | −$879.5K | −$1.6M |
| Interest expense | $338.8KT (source: Derived: trailing 12 months at year end) | n/a | n/a | n/a |
| Pretax income | $1.1MT (source: Derived: trailing 12 months at year end) | n/a | −$626.9K | −$1.3M |
| Tax | −$413.6KT (source: Derived: trailing 12 months at year end) | n/a | −$796.2K | −$483.7K |
| NPAT | $1.5MM (source: ASX (Markit)) | −$1.7MM (source: ASX (Markit)) | $169.3K | −$780.4K |
| Net interest income | −$321.4KT (source: Derived: trailing 12 months at year end) | n/a | $137.8K | $39.9K |
| EPS basic | $0.003T (source: Derived: trailing 12 months at year end) | −$0.004 | $0.000 | −$0.002 |
| EPS diluted | $0.003T (source: Derived: trailing 12 months at year end) | −$0.004 | $0.000 | −$0.002 |
| Shares | n/a | n/a | 446.9M | 461.1M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E, Full Year Statutory Accounts & Annual ReportAnnual Results28 Aug 2026via asx_announcements
- FY26 Full Year Results & FY27 Guidance Investor PresentationFull Year Results28 Aug 2026via asx_announcements
- FY26 Full Year Results & Investor WebinarFull Year Results28 Aug 2026via asx_announcements
- FY26 Full Year Results WebinarFull Year Results19 Aug 2026via asx_announcements
- Cessation of Quarterly ReportingQuarterly Report12 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report24 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Year ResultsHalf Year Results27 Feb 2026via asx_announcements
- Half Year Report & AccountsHalf Year Results27 Feb 2026via asx_announcements
- Half Year Results PresentationHalf Year Results27 Feb 2026via asx_announcements
Showing 10 of 41 reports